ARMLUPEG
Armlupeg is a leukocyte growth factor indicated for use in adult and pediatric patients, including newborns. It is primarily used to reduce the risk of infection, specifically febrile neutropenia, in patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy. Additionally, the drug is approved to improve survival rates in individuals who have experienced acute exposure to myelosuppressive doses of radiation. It is not intended for the mobilization of peripheral blood progenitor cells during hematopoietic stem cell transplantation.
How ARMLUPEG Works
Armlupeg functions as a colony-stimulating factor that targets hematopoietic cells. The drug works by binding to specific receptors located on the surface of these cells. This binding action triggers the proliferation, differentiation, and commitment of the cells, ultimately leading to their functional activation. By stimulating these biological processes, the medication helps manage the effects of myelosuppression.
Details
- Status
- Prescription
- First Approved
- 2025-11-28
- Routes
- SOLUTION
- Dosage Forms
- INJECTION
ARMLUPEG Approval History
What ARMLUPEG Treats
2 indicationsARMLUPEG is approved for 2 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Febrile Neutropenia
- Acute Radiation Syndrome
ARMLUPEG is a lower-cost alternative to Neulasta with no clinically meaningful differences. Requires prescriber approval to substitute.
Drugs Similar to ARMLUPEG
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ARMLUPEG FDA Label Details
ProIndications & Usage
Armlupeg is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). Limitations of Use Armlupeg is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.1 Patients with Canc...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.